Michel Detheux - Oct 15, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: Chief Executive Officer
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol: ITOS
Transactions as of: Oct 15, 2021
Transactions value $: -$51,424
Form type: 4
Date filed: 10/19/2021, 08:01 PM
Previous filing: Sep 27, 2021
Next filing: Oct 25, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITOS	Common Stock	Sale	-$45.8K	-1.64K	-1.65%	$28.01	97.4K	Oct 15, 2021	Direct	F1, F2
transaction	ITOS	Common Stock	Sale	-$5.63K	-201	-0.21%	$28.00	97.2K	Oct 19, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.06, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.06, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.